Engility: Expands AI-driven R&D in the CNS field with Element Biosciences, with a total amount of up to $94.75 million.

On March 26, AI Silica announced on the Hong Kong Stock Exchange that it has reached an expanded AI-driven research and development collaboration with Tenacia Biotechnology Co., Limited. According to the terms of the agreement, both parties will use generative AI to develop an innovative candidate molecule with specific attributes for challenging neurological diseases, and advance it to the preclinical candidate drug stage to meet differentiated clinical needs. The total transaction amount for this expanded collaboration can reach up to $94.75 million. AI Silica is expected to receive payments from Elementa Bio in the near future and milestone payments.